Newmed

NewMed Medical (Shanghai) Co., Ltd. is a high-end medical device company focused on the research, development, and commercialization of transcatheter heart valve systems. Founded in 2015, the company addresses structural heart diseases through a comprehensive portfolio that covers all four cardiac valves: aortic, mitral, tricuspid, and pulmonary. Its lead product candidates, including the Prizvalve® for aortic stenosis and Mi-thos® for mitral regurgitation, are designed to provide minimally invasive alternatives to traditional surgery. NewMed has attracted significant investment from prominent firms such as Temasek, Sequoia China, and OrbiMed, highlighting its position as a leading innovator in the Chinese cardiovascular intervention market. The company maintains a robust R&D platform and manufacturing capabilities in Shanghai and Chengdu.